These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37112726)

  • 41. Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine.
    Fernandez-Sainz I; Medina GN; Ramirez-Medina E; Koster MJ; Grubman MJ; de Los Santos T
    Virology; 2017 Feb; 502():123-132. PubMed ID: 28039799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle.
    Guo HC; Sun SQ; Jin Y; Yang SL; Wei YQ; Sun DH; Yin SH; Ma JW; Liu ZX; Guo JH; Luo JX; Yin H; Liu XT; Liu DX
    Vet Res; 2013 Jul; 44(1):48. PubMed ID: 23826638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and protective efficacy of 3A truncated negative marker foot-and-mouth disease virus serotype A vaccine.
    Dhanesh VV; Hosamani M; Basagoudanavar SH; Saravanan P; Biswal JK; Tamil Selvan RP; Madhavan A; Sehrish K; Sanyal A; Sreenivasa BP
    Appl Microbiol Biotechnol; 2020 Mar; 104(6):2589-2602. PubMed ID: 32002597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Coinjection of a vaccine and anti-viral agents can provide fast-acting protection from foot-and-mouth disease.
    You SH; Kim T; Choi JH; Park G; Lee KN; Kim B; Lee MH; Kim HS; Kim SM; Park JH
    Antiviral Res; 2017 Jul; 143():195-204. PubMed ID: 28454913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological responses after vaccination of growing pigs with foot-and-mouth disease trivalent (type O, A and Asia1) vaccine.
    Lee HS; Lee NH; Seo MG; Ko YJ; Kim B; Lee JB; Kim JS; Park S; Shin YK
    Vet Microbiol; 2013 Jun; 164(3-4):239-45. PubMed ID: 23490554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The detection of long-lasting memory foot-and-mouth disease (FMD) virus serotype O-specific CD4
    Mitoma S; Carr BV; Harvey Y; Moffat K; Sekiguchi S; Charleston B; Norimine J; Seago J
    Immunology; 2021 Oct; 164(2):266-278. PubMed ID: 34003490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease virus in pigs vaccinated with multi-epitope protein vaccine incorporated with poly(I:C).
    Cao Y; Lu Z; Li D; Fan P; Sun P; Bao H; Fu Y; Li P; Bai X; Chen Y; Xie B; Liu Z
    Vet Microbiol; 2014 Jan; 168(2-4):294-301. PubMed ID: 24345411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selection of vaccine strains for serotype O foot-and-mouth disease viruses (2007-2012) circulating in Southeast Asia, East Asia and Far East.
    Mahapatra M; Upadhyaya S; Aviso S; Babu A; Hutchings G; Parida S
    Vaccine; 2017 Dec; 35(51):7147-7153. PubMed ID: 29157957
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection.
    Kerfua SD; Haydon DT; Wilsden G; Ludi A; King DP; Okurut RA; Atim S; Dhikusooka MT; Kyakuwa I; Motta P; Paton DJ
    Vaccine; 2024 Dec; 42(26):126325. PubMed ID: 39270355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle.
    Steigerwald R; Brake DA; Barrera J; Schutta CJ; Kalla M; Wennier ST; Volkmann A; Hurtle W; Clark BA; Zurita M; Pisano M; Kamicker BJ; Puckette MC; Rasmussen MV; Neilan JG
    Vaccine; 2020 Jan; 38(4):769-778. PubMed ID: 31718901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two Cross-Protective Antigen Sites on Foot-and-Mouth Disease Virus Serotype O Structurally Revealed by Broadly Neutralizing Antibodies from Cattle.
    Li K; He Y; Wang L; Li P; Wang S; Sun P; Bao H; Cao Y; Liu X; Zhu G; Song Y; Bai X; Ma X; Fu Y; Yuan H; Zhang J; Wang J; Chen Y; Li D; Lou Z; Liu Z; Lu Z
    J Virol; 2021 Oct; 95(21):e0088121. PubMed ID: 34406868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine.
    Qian P; Li XM; Jin ML; Peng GQ; Chen HC
    Vaccine; 2004 Jun; 22(17-18):2129-36. PubMed ID: 15149769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and serology based efficacy assessment of a trivalent foot-and-mouth disease vaccine.
    Al Amin M; Ali MR; Islam MR; Alam ASMRU; Shill DK; Rahman MS; Siddique MA; Sultana M; Hossain MA
    Vaccine; 2020 Jul; 38(32):4970-4978. PubMed ID: 32535015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of intradermally administrated E2 subunit vaccines in reducing horizontal transmission of classical swine fever virus.
    Dortmans JC; Loeffen WL; Weerdmeester K; van der Poel WH; de Bruin MG
    Vaccine; 2008 Feb; 26(9):1235-42. PubMed ID: 18242794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Potential Adjuvanticity of CAvant
    Ahn YH; Chathuranga WAG; Shim YJ; Haluwana DK; Kim EH; Yoon IJ; Lim YT; Shin SH; Jo H; Hwang SY; Kim HM; Lee MJ; Park JH; Yoo SS; Lee JS
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides.
    Heshmati L; Rezayat SM; Madani R; Emami T; Jafari MR; Golchinfar F; Kazemi M; Azimi Dezfouli SM
    Arch Razi Inst; 2021 Nov; 76(5):1183-1190. PubMed ID: 35355777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
    Barrera J; Schutta C; Pisano M; Grubman MJ; Brake DA; Miller T; Kamicker BJ; Olutunmbi F; Ettyreddy D; Brough DE; Butman BT; Neilan JG
    Vaccine; 2018 Feb; 36(8):1078-1084. PubMed ID: 29358056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs.
    Eblé PL; de Bruin MG; Bouma A; van Hemert-Kluitenberg F; Dekker A
    Vaccine; 2006 Feb; 24(9):1274-81. PubMed ID: 16289709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic Foot-and-Mouth Disease Vaccination in Cattle Promotes Specific Antibody-Secreting Cells at the Respiratory Tract and Triggers Local Anamnestic Responses upon Aerosol Infection.
    Pega J; Di Giacomo S; Bucafusco D; Schammas JM; Malacari D; Barrionuevo F; Capozzo AV; Rodríguez LL; Borca MV; Pérez-Filgueira M
    J Virol; 2015 Sep; 89(18):9581-90. PubMed ID: 26157128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.